Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer

Fallowfield, Lesley; Atkins, Louise; Catt, Susan; Cox, Anna; Coxon, C.; Langridge, C.; Morris, R.; Price, M.

doi:10.1093/annonc/mdj044

Cited by 156 publications

(99 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…How well and for how long oncology patients take prescribed oral therapies is of growing importance as the availability and use of oral antineoplastic agents increases. Oncology patients express a preference for oral treatments, 22 hence, identifying those at risk of nonpersistence, quantifying the extent of nonpersistence, and developing strategies to improve persistence are of vital importance.…”

Section: Methodsmentioning

confidence: 99%

“…[22][23][24][25] These included age; the number of comorbidities such as diabetes, cardiovascular disease, and respiratory disease; and the number of different pharmacological agents prescribed in the year before tamoxifen initiation. Additional variables also considered were the use of antidepressant, antipsychotic, or anxiolytic/hypnotic agents, and the presence of cognitive or functional impairment such as Parkinson disease or dementia.…”

Section: Potential Determinants Of Nonpersistencementioning

confidence: 99%

See 1 more Smart Citation

Early discontinuation of tamoxifen

Barron

Connolly

Bennett

et al. 2007

Cancer

259

248

View full text Add to dashboard Cite

BACKGROUND.Five years of treatment provides the optimum duration of tamoxifen therapy for the prevention of breast cancer recurrence and mortality. Durations of adjuvant tamoxifen therapy less than 5 years are associated with poorer outcomes for breast cancer patients. The purpose of the study was to assess rates of tamoxifen nonpersistence (early discontinuation) in women aged 35 years or older using prescription refill data from a national prescribing database.METHODS.A cohort of 2816 women commencing tamoxifen as initial hormonal therapy was identified between January 2001 and January 2004. The cumulative tamoxifen persistence rate was calculated for these women and the relation between nonpersistence and clinical and demographic variables assessed.RESULTS.Within 1 year of commencing treatment the cumulative tamoxifen nonpersistence rate was 22.1%. This is twice the rate of treatment discontinuation observed in other studies by this time. By the end of follow‐up at 3.5 years, the cumulative nonpersistence rate had increased to 35.2%. Determinants of nonpersistence identified included age and a history of antidepressant use.CONCLUSIONS.The rate of nonpersistence with tamoxifen therapy is higher than previously reported. This study demonstrates that persistence with tamoxifen cannot be assumed and raises concerns about persistence with other oral hormonal therapies for breast cancer and oral antineoplastics in general. Oncologists need to identify those at risk of nonpersistence and develop strategies to combat this barrier to treatment success. Cancer 2007. © 2007 American Cancer Society.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Potential Determinants Of Nonpersistencementioning

confidence: 99%

Early discontinuation of tamoxifen

Barron

Connolly

Bennett

et al. 2007

Cancer

259

248

View full text Add to dashboard Cite

show abstract

“…As part of a wider study investigating breast cancer patients' preferences for different routes of administration of hormone therapy [13], we also examined the adherence of those receiving medication. We recorded self-reported intentional and non-intentional non-adherence and the different personality and demographic factors associated with this.…”

Section: Factors Related To Non-adherencementioning

confidence: 99%

Intentional and non-intentional non-adherence to medication amongst breast cancer patients

Atkins

Fallowfield

2006

European Journal of Cancer

217

228

View full text Add to dashboard Cite

This study aimed to investigate the prevalence of and factors associated with nonadherence to medication amongst a sample of breast cancer patients. 131 women with stable disease were interviewed and completed standardised psychological measures. 55% of women reported non-adherence to medication frequently or occasionally, with younger women and those who disliked taking their medication being significantly less adherent (P =0.015, P =0.001). Women who deliberately omitted taking their tablets occasionally or frequently had significantly lower scores, indicative of a weaker influence, on 'internal' and 'powerful others' dimensions of health locus of control (P =0.032, P =0.009). Despite a life-threatening diagnosis, patients may not adhere to medication representing a potential missed opportunity for health gain and waste of resources. Furthermore, interpretation of clinical trial data may be misleading without adherence information. More r esear ch is need ed to iden tify those at risk for non-adherence. If other routes of administration are available these options should be discussed with patients to maximise efficacy of therapy.

show abstract

“…7,20,21,[23][24][25]38,39,50,51,[55][56][57][58][59] Although the MEMS is touted as a "gold standard" measurement in medication compliance, only 6 of the adult studies 8,48,52,53,60 and one pediatric study 61 used this method of measurement. MEMS is not considered to be a practical tool in the clinical setting due to its excessive cost.…”

Section: An Integrative Review Of Literature On Measurement Of Adherementioning

confidence: 99%

“…20,21,24,25,50,58 Although type of disease is known to influence adherence in certain circumstances, [77][78][79][80] there is a paucity of information on cancer stage and its effects on adherence, and these data need to be included in future adherence research. In cancer patients, the gravity of the disease may produce adherence in some patients.…”

Section: Patient Characteristics Contributing To Adherence and Implicmentioning

confidence: 99%

Assessment and Measurement of Adherence to Oral Antineoplastic Agents

Spoelstra¹,

Given²

2011

Seminars in Oncology Nursing

View full text Add to dashboard Cite

OBJECTIVES:The increase in oral anticancer medications with complex regimens creates a need to assure patients are taking therapeutic dosages as prescribed. This article reviews the assessment and measurement of adherence to oral antineoplastic agents. DATA SOURCE:Research and journal articles from CINAHL and Pub Med. CONCLUSION:Assessing and measuring adherence to oral antineoplastic should include three dimensions: the percentage of medications taken, the duration, and the timing of taking the medication. IMPLICATIONS FOR PRACTICE:Clinicians need to conduct ongoing assessment and measurement of adherence to oral antineoplastic agents. This includes eliciting patient report of adherence, pill counts, drug diaries, and pharmacy or medical record audits.

show abstract

Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer

Cited by 156 publications

References 19 publications

Early discontinuation of tamoxifen

Early discontinuation of tamoxifen

Intentional and non-intentional non-adherence to medication amongst breast cancer patients

Assessment and Measurement of Adherence to Oral Antineoplastic Agents

Contact Info

Product

Resources

About